SCHEMBL2052704

SCHEMBL2052704

O=C(O)c1c[nH]c2cnccc12

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DYRK1A Q13627 8/20 0.51
NFATC1 O95644 5/20 0.51
GSK3B P49841 4/20 0.51
HASPIN Q8TF76 1/20 0.48
KDM4C Q9H3R0 2/20 0.47
KDM4E B2RXH2 1/20 0.47
MEN1 O00255 1/20 0.47
KDM6B O15054 1/20 0.47
KDM4A O75164 1/20 0.47
ALDH1A1 P00352 1/20 0.47
MAPT P10636 1/20 0.47
THRB P10828 1/20 0.47
KMT2A Q03164 1/20 0.47
KDM4D Q6B0I6 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
F7 P08709 1/20 0.46
F3 P13726 1/20 0.46
CYP2D6 P10635 1/20 0.46
CYP2C9 P11712 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30101234 1.00 DYRK1A (0.51) DYRK1ANFATC1GSK3BHASPINKDM4C
SCHEMBL2833860 0.90 CYP1A2 (0.51) DYRK1ANFATC1GSK3BHASPINKDM4E
SCHEMBL2628950 0.88 CYP2D6 (0.48) DYRK1ANFATC1GSK3BHASPINMEN1
SCHEMBL3217902 0.86 HASPIN (0.64) DYRK1ANFATC1GSK3BHASPINKDM4E
SCHEMBL22300127 0.86 DYRK1A (0.49) DYRK1ANFATC1GSK3BHASPINCYP2D6
SCHEMBL30924488 0.86 HASPIN (0.64) DYRK1ANFATC1GSK3BHASPINKDM4E
SCHEMBL4357845 0.86 ALDH1A1 (0.59) DYRK1ANFATC1GSK3BHASPINKDM4E
SCHEMBL2817519 0.85 NAMPT (0.51) HASPINKDM4CKDM4EMEN1KDM6B
SCHEMBL4268366 0.84 GPR84 (0.51) DYRK1ANFATC1GSK3BMEN1ALDH1A1
SCHEMBL3887018 0.83 DYRK1A (0.46) DYRK1ANFATC1GSK3BHASPINALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100249123-A1 NOVEL BENZAMIDE DERIVATIVES AS MODULATORS OF THE FOLLICLE STIMULATING HORMONE ADDEX PHARMA SA (CH) 2010-09-30 US claimed
US-12577243-B2 Monoacylglycerol lipase modulators JANSSEN PHARMACEUTICA NV (BE) 2026-03-17 US disclosed
EP-3856178-B1 MONOACYLGLYCEROL LIPASE MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2026-03-11 EP disclosed
US-12509453-B2 BRM/BRG1 inhibitors and uses thereof FOGHORN THERAPEUTICS INC. (US) 2025-12-30 US disclosed
US-11820766-B2 Monoacylglycerol lipase modulators JANSSEN PHARMACEUTICA NV (BE) 2023-11-21 US disclosed
US-20230145249-A1 Monoacylglycerol Lipase Modulators JANSSEN PHARMACEUTICA NV (BE) 2023-05-11 US disclosed
US-20220332713-A1 Monoacylglycerol Lipase Modulators JANSSEN PHARMACEUTICA NV (BE) 2022-10-20 US disclosed
US-20220119378-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2022-04-21 US disclosed
US-20220119378-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2022-04-21 US disclosed
EP-3856178-A1 MONOACYLGLYCEROL LIPASE MODULATORS Janssen Pharmaceutica NV (BE) 2021-08-04 EP disclosed
EP-2519520-A1 [4-(3-AMINOMETHYL-PHENYL)-PIPERIDIN-1-YL]-(1H-PYRROLOPYRIDINYL)-METHANONE DERIVATIVES AS TRYPTASE INHIBITORS SANOFI (FR) 2012-11-07 EP disclosed
WO-2012137089-A1 PYRROLO [2, 3 -D] PYRIMIDINE DERIVATIVES AS INHIBITORS OF TROPOMYOSIN- RELATED KINASES PFIZER LIMITED (GB) 2012-10-11 WO disclosed
US-20120245199-A1 [4 [4-(AMINOMETHYL-2-FLUORO-PHENYL)-PIPERIDIN-1-YL]-(1H-PYRROLO-PYRIDIN-YL)-METHANONES AND SYNTHESIS THEREOF SANOFI (FR) 2012-09-27 US disclosed
US-20120245199-A1 [4 [4-(AMINOMETHYL-2-FLUORO-PHENYL)-PIPERIDIN-1-YL]-(1H-PYRROLO-PYRIDIN-YL)-METHANONES AND SYNTHESIS THEREOF SANOFI (FR) 2012-09-27 US disclosed
US-20120245199-A1 [4 [4-(AMINOMETHYL-2-FLUORO-PHENYL)-PIPERIDIN-1-YL]-(1H-PYRROLO-PYRIDIN-YL)-METHANONES AND SYNTHESIS THEREOF SANOFI (FR) 2012-09-27 US disclosed
WO-2011078984-A1 [4[4-(5-AMINOMETHYL-2-FLUORO-PHENYL)-PIPERIDIN-1-YL]-(1H-PYRROLO-PYRIDIN-YL)-METHANONES AND SYNTHESIS THEREOF SANOFI (FR) 2011-06-30 WO disclosed
WO-2011078984-A1 [4[4-(5-AMINOMETHYL-2-FLUORO-PHENYL)-PIPERIDIN-1-YL]-(1H-PYRROLO-PYRIDIN-YL)-METHANONES AND SYNTHESIS THEREOF SANOFI (FR) 2011-06-30 WO disclosed
US-20100249123-A1 NOVEL BENZAMIDE DERIVATIVES AS MODULATORS OF THE FOLLICLE STIMULATING HORMONE ADDEX PHARMA SA (CH) 2010-09-30 US disclosed
WO-2009108551-A2 HETEROARYL AMIDE ANALOGUES H. LUNDBECK A/S (DK) 2009-09-03 WO disclosed
WO-1996011929-A1 BIHETEROARYL-CARBONYL AND CARBOXAMIDE DERIVATIVES WITH 5HT 2C/2B ANTAGONISTS ACTIVITY SMITHKLINE BEECHAM PLC (GB) 1996-04-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220332713-A1 Monoacylglycerol Lipase Modulators MGLL, LPL, PNLIP DYRK1A 2576/4885NFATC1 4595/4885GSK3B 948/4885
US-12577243-B2 Monoacylglycerol lipase modulators MGLL, LPL, FAAH DYRK1A 3493/4885NFATC1 4322/4885GSK3B 914/4885
US-20100249123-A1 NOVEL BENZAMIDE DERIVATIVES AS MODULATORS OF THE FOLLICLE STIMULATING HORMONE FSHR, GNRHR, SHBG DYRK1A 4461/4885NFATC1 2966/4885GSK3B 4812/4885
US-20230145249-A1 Monoacylglycerol Lipase Modulators MGLL, LPL, PNLIP DYRK1A 2576/4885NFATC1 4595/4885GSK3B 948/4885
US-12509453-B2 BRM/BRG1 inhibitors and uses thereof SMARCC1, SMARCC2, SMARCA1 DYRK1A 4096/4885NFATC1 2978/4885GSK3B 3716/4885
US-20220119378-A1 COMPOUNDS AND USES THEREOF VHL, CLN6, TFEB DYRK1A 4550/4885NFATC1 4194/4885GSK3B 3110/4885
US-11820766-B2 Monoacylglycerol lipase modulators MGLL, LPL, PNLIP DYRK1A 2576/4885NFATC1 4595/4885GSK3B 948/4885
US-20120245199-A1 [4 [4-(AMINOMETHYL-2-FLUORO-PHENYL)-PIPERIDIN-1-YL]-(1H-PYRROLO-PYRIDIN-YL)-METHANONES AND SYNTHESIS THEREOF CMA1, TPSB2, TPH1 DYRK1A 3021/4885NFATC1 1022/4885GSK3B 1875/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.